RIGEL PHARMACEUTICALS INC 8-K

What Happened
Rigel Pharmaceuticals, Inc. (RIGL) announced financial results for the fourth quarter ended December 31, 2025, in a press release dated March 3, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K (filed Mar 3, 2026) under Item 2.02 (Results of Operations and Financial Condition). The filing also includes the Interactive XBRL cover page (Exhibit 104).

Key Details

• Filing date: March 3, 2026 (Form 8-K).
• Reporting period: Quarter ended December 31, 2025 (fourth quarter) and full year 2025.
• Exhibit filed: 99.1 — Press Release titled “Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.”
• Administrative items: Exhibit 104 (Cover Page Interactive Data File) included; 8-K signed by Raymond J. Furey, EVP & General Counsel.

Why It Matters
This 8-K formally notifies investors that Rigel has released its Q4 and full-year 2025 results and a business update; the press release is the primary source for the actual earnings, revenue, cash position, and any guidance or operational updates. Retail investors should read the attached press release for the specific financial figures and any commentary on results or near-term plans, and monitor for follow-up filings (e.g., 10-K, earnings presentation, or an earnings call) that may provide more detailed financial statements and management discussion.